TScan Therapeutics, Inc.
TCRX
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-2ā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.09
Price-6.04%
-$0.07
1Y
Price
Market Cap
$61.687m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1156.2%
EBITDA Margin-1201.3%
Net Profit Margin-1123.1%
Free Cash Flow MarginRevenue
$6.961m
+147.2%
1y CAGR+38.7%
3y CAGR+37.4%
5y CAGREarnings
-$136.775m
-7.3%
1y CAGR-28.6%
3y CAGR-30.3%
5y CAGREPS
-$1.09
+4.4%
1y CAGR+23.6%
3y CAGR+9.0%
5y CAGRBook Value
$176.714m
$298.561m
Assets$121.847m
Liabilities$64.404m
DebtDebt to Assets
21.6%
-0.5x
Debt to EBITDAFree Cash Flow
-$131.252m
-14.5%
1y CAGR-27.8%
3y CAGR-26.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company